A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma. by Dawson, M et al.
40
A sensitive method for the determination of oxycodone
concentrations in plasma by high-performance liquid
chromatography (HPLC)–electrospray ionization–triple quadrupole
mass spectrometry is described. The method is rugged, reliable,
selective, and rapid with a run time of 2 min. One milliliter of
plasma is made basic and extracted with 2-mL duplicate portions 
of 2% isoamyl alcohol in n-butyl chloride. The combined extracts
are then evaporated to dryness, reconstituted in 100 µL of the
mobile phase (15% methanol–85% water containing 0.1% 
acetic acid), and injected onto the HPLC. The limit of quantitation 
is 1 ng/mL, and the estimated limit of detection is 33 pg/mL 
(signal-to-noise = 3). Standard curves are linear over the range 
of 1 to 100 ng/mL with all correlation coefficient values greater
than 0.9989. The method is used to determine the concentration 
of oxycodone in human plasma following the intravenous infusion 
of doses ranging from 5 to 15 mg in which the analysis of over 
3000 plasma samples is required.
Introduction
Oxycodone (4,5-epoxy-14-hydroxy-3-methoxy-17-methylmor-
phinan-6-one) (Figure 1) is a potent opioid agonist with a dose-
dependent analgesic effect (1) comparable with morphine (Figure
1) (2) and has been available for clinical use since 1915 (3).
Clinically, oxycodone is administered alone as immediate or mod-
ified release products or in combination with mild analgesics (2)
for the management of moderate to severe pain.
The quantitation of oxycodone concentrations in biological
fluids by gas chromatography (GC) is not straightforward because
of the need to derivatize the 14-hydroxyl group (3–6), and none of
the derivatives evaluated by us exhibited satisfactorily on machine
stability. Similarly, the fronting and tailing of the oxycodone peak
when high-performance liquid chromatography (HPLC) is used
causes reductions in sensitivity and selectivity. Broglé (7) investi-
gated the causes of the peak fronting of oxycodone under a
number of HPLC conditions. It was concluded that the cause of
peak fronting was not the coexistence of keto–enol tautomers in
the solutions analyzed, but rather the presence of ketone–gem-
diol and ketone hemi-ketal equilibria species resulting from reac-
tions with water and methanol, respectively, in the acidic mobile
phase (Figure 2). These equilibria are temperature dependent,
and fronting can be minimized by raising the column tempera-
ture.
Literature methods for the determination of oxycodone also
include radioimmunoassay and thin-layer chromatography
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Figure 1. The chemical structure of (A) oxycodone, (B) naloxone, and 
(C) morphine.
Figure 2. Equilibria between (A) the ketone–gemdiol, (B) oxycodone, and 
(C) ketone–hemiketal of oxycodone.
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(4,8–10); however, these methods are usually only used for
screening purposes because they lack either the required degree
of sensitivity or selectivity for use in pharmacokinetic studies.
HPLC–electrochemical detection (ECD) methods have been
reported (11–13). Although these have limits of quantitation in
the low nanograms-per-milliliter range, they require extensive
work-up. GC–nitrogen–phosphorus detection (NPD) methods
have been reported (14–16). These have limits of detection in the
range of 1.8 to 3 ng/mL, but no data on the limit of quantitation
have been provided. A GC–ECD method, which included a deriva-
tization step with heptafluorobutyrlimidazole, had the reported
lowest point on the standard curve of 10 ng/mL (17).
Various GC–mass spectrometry (MS) methods report similar
sensitivity to HPLC–ECD and GC–NPD methods. One GC–MS
method for measuring oxycodone in urine had a limit of quanti-
tation of 25 ng/mL after extensive sample preparation, which
included sequential derivatization with 2% methoxyamine in
pyridine followed by propionic anhydride (5). Another described a
method based on the GC–MS analysis of the trimethylsilyl ether
derivatives of oxycodone that was linear over the range of 150 to
1500 ng/mL (4). Others have reported methods in which sample
preparation included derivatization with acetic anhydride–pyri-
dine. The linear ranges of the methods were 50–1000 ng/mL (6)
and 0.2–100 ng/mL (2).
Although many analytical methods have been reported in the
literature for the determination of oxycodone in biological fluids,
none were suitable for the purposes of our study, which required
the rapid analysis of over 3000 plasma samples. Reported
methods either lacked the desired degree of sensitivity or were
excessively time consuming with respect to work-up and HPLC
run time.
The method described in this study has comparable limits of
quantitation to the more sensitive methods previously reported
in the literature, but has significant advantages (such as the
sample preparation was simple and the run time very short).
Sample preparation consisted of the addition of an internal stan-
dard (naloxone) followed by the liquid–liquid extraction of the
plasma sample and a subsequent concentration of the extract
prior to injection onto the liquid chromatograph (LC)–MS–MS.
Triple quadrupole MS provided unsurpassed selectivity in which
the analyte and internal standard were separated by mass and not
time. Retention times were 1.30 min for naloxone and 1.41 min
for oxycodone, and the run time was 2 min, thus allowing for very
high throughput of samples.
The mobile phase consisted of 15% methanol–85% water (v/v)
with 0.1% acetic acid, and the column temperature was 60°C.
These conditions produced minimal fronting and tailing with
almost symmetrical peaks.
A highly sensitive assay was required for pharmacokinetic
studies (dose range from 5 to 15 mg), and in order to generate the
required data it was necessary to follow the time course of oxy-
codone for as long as possible after the administration of each
dose. The method developed and reported in this study is more
sensitive, more selective, less complicated, and has a significantly
shorter analysis time than other published assays, allowing for




Reference samples of oxycodone hydrochloride and naloxone
hydrochloride were obtained from Boots (Sydney, Australia) and
Sigma (St. Louis, MO), respectively. HiPerSolv-grade n-butyl
chloride was obtained from BDH Chemicals (Melbourne,
Australia); SurfaSil was obtained from Pierce (Rockford, IL); and
all other chemicals used were analytical-reagent grade. Water was
purified by a Milli-Q system obtained from Millipore (Sydney,
Australia).
All glassware was supplied by Alltech (Sydney, Australia). A
Searle vortex mixer (Buchler Instruments, Ft. Lee, NJ) and a
Medos JAK vacuum evaporator (Dynavac Engineering, Sydney,
Australia) were used in the sample preparation.
Preparation of glassware
Glassware was silanized by immersion in a 5% solution of
SurfaSil in n-hexane for 10 min and then rinsed with acetone and
dried in an oven at 100°C for 1 h.
Instrumentation
Analyses were performed using a PerkinElmer (Melbourne,
Australia) Series 200 autosampler, micro PerkinElmer series 200
LC pump, vacuum degasser, and PerkinElmer SCIEX API 365
LC–MS–MS with Turbo IonSpray. The Zorbax SB-C18 5-µm
column (50- × 2.1-mm i.d.) (Agilent, Melbourne, Australia) was
maintained at 60°C. The mobile phase consisted of 15%
methanol–85% water containing 0.1% acetic acid, the flow rate
was 0.2 mL/min, and the injection volume was 10 µL.
The MS was run in multiple reaction monitoring mode. The
nebulizing gas flow rate of the Turbo IonSpray was 1.25 L/min.
The electrospray ion source voltage was 5000 V, the orifice voltage
was +30 V, and the source temperature was 300°C. The ring
voltage was +220 V, the Q0 energy was –10 V, and RO2 was –35 V
in order to give a collision energy of 25 V for both oxycodone and
naloxone. The curtain gas was nitrogen at a flow rate of 1.25
L/min. The ions monitored were m/z 316.1 (Q1) → 298.1 (Q3) for
oxycodone and m/z 328.1 (Q1) → 310.1 (Q3) for naloxone. The
dwell time was 200 ms for both oxycodone and naloxone.
Sample preparation
Blood samples obtained from healthy human subjects before
and after receiving oxycodone were placed in heparinized blood-
collecting tubes and centrifuged at 1500 g for 10 min. The plasma
was separated and stored at –20°C until analysis.
A stock solution of 10 mg/mL oxycodone (as the hydrochloride)
was prepared in Milli-Q water. Standards in plasma were then pre-
pared by adding volumes of stock solution to drug-free plasma to
give final concentrations covering the range of 1 to 100 ng/mL.
The working internal standard solution (670 ng/mL naloxone
hydrochloride) was prepared in Milli-Q water.
One-milliliter aliquots of the plasma samples and the plasma
oxycodone standard solutions were pipetted into 4-mL glass vials
containing the internal standard (naloxone hydrochloride, 10 µL,
6.7 ng) and made alkaline to pH 9 with 200 µL carbonate buffer.
The carbonate buffer was prepared from a saturated sodium
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hydrogen carbonate solution, which was adjusted to pH 9 with a
saturated sodium carbonate solution. The extraction solvent, 2%
isoamyl alcohol in n-butyl chloride (2 mL), was added, and the
mixture was vortex mixed for 10 min followed by centrifugation
at 2000 g for 5 min. The samples were frozen at –80°C for 20 min
and the organic layer decanted into a 2-mL glass vial and evapo-
rated to dryness under vacuum at 40°C. The sample was re-
extracted, and the extraction residues were combined and
reconstituted in a 100-µL mobile phase, vortex mixed (30 s), cen-
trifuged (1 min), and then transferred into a 250-µL silanized
glass insert. An aliquot (10 µL) was injected onto the HPLC.
Results and Discussion
Sample preparation considerations
In order to increase the sensitivity of this assay, several factors
were addressed. First, all glassware was deactivated with a
silanizing reagent to minimize the loss of oxycodone through
binding to active sites on the glassware. Second, ultrahigh-purity
solvents were used to minimize solvent impurity interferences.
Third, 2% isoamyl alcohol in n-butyl chloride was used as the
extraction solvent because it caused no emulsification with
plasma, which was noted with other extraction solvents evalu-
ated.
Chromatography
Chromatographic conditions were optimized to provide both
short retention times and an adequate peak shape in order to
allow for the quantitation of oxycodone and naloxone. Factors
were taken into account when selecting the final conditions such
as our observation that increasing concentrations of methanol in
the mobile phase reduced the sensitivity of oxycodone because of
mobile phase ion suppression. Naidong (18) reported that mobile
phases with little organic component resulted in poor spray con-
ditions because of the high surface tension of the aqueous
droplets, thus adversely affecting sensitivity. The methanol con-
tent selected in this study was that which gave short retention
times without adversely affecting sensitivity.
It was also found that the addition of 0.1% acetic acid not only
improved the retention time stability of both analytes, but also
provided an increase in sensitivity. The mobile phase selected for
this assay provided the required sensitivity with both short reten-
tion times and nearly symmetrical peaks.
Peak symmetry was calculated using the 4.4% peak height/peak
asymmetry factor. Five replicate chromatograms of extracts from
plasma containing 100 ng/mL oxycodone gave an asymmetry
value of 1.4, which indicated that there was only slight tailing
associated with these peaks.
The sensitivity of the assay was excellent as shown in Figure 3,
which shows the chromatograms of an extract from 1 mL of
plasma spiked with 1 ng oxycodone (Figure 3C) and 6.7 ng
naloxone (Figure 3D) and a representative blank for each transi-
tion (Figures 3A and 3B).
Electrospray mass spectra
The fragmentation of the product ions of oxycodone and
naloxone are shown in Figures 4A and 4B, respectively. The pre-
dominant peaks for oxycodone (Figure 4A) were m/z 316.1 (cor-
responding with MH+) and m/z 298.1 (corresponding with MH+–
H2O). The predominant peaks for naloxone (Figure 4B) were m/z
328.1 (corresponding with MH+) and m/z 310.1 (corresponding
with MH+–H2O). Q3 scan conditions were optimized by infusing
Figure 3. Chromatograms of an extract from (A and B) 1 mL blank plasma and
(C) 1 mL plasma spiked with 1 ng oxycodone and (D) 6.7 ng naloxone. The
transitions were oxycodone (m/z 316  298) and naloxone (m/z 328  310).
Figure 4. The collision activated decomposition spectrum of the protonated
molecule of (A) oxycodone (m/z 316.1) and (B) naloxone (m/z 328.1).
A B
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a solution of analyte (oxycodone or naloxone) in the mobile phase
via a syringe pump (2.5 mL/h) and using Autotune Optimisation
software.
Retention times
The retention times for oxycodone and naloxone (internal stan-
dard) were 1.41 and 1.30 min, respectively.
Linearity
Standard curves covering the concentration range of 1 to 100
ng/mL oxycodone in plasma were found to be linear. Six standard
curves had correlation coefficient values ranging from 0.9989 to
0.9999.
Limit of quantitation and limit of detection
The limit of quantitation was 1 ng/mL and the limit of detection
was 33 pg/mL (signal-to-noise = 3).
Within-run precision
A measure of within-run precision was estimated from the coef-
ficient of variation of samples (n = 6) processed in the same batch
and analyzed on the same day. An assay of six replicate samples at
1, 10, and 100 ng/mL gave coefficients of variation of 8.6%, 1.9%,
and 1.9%, respectively.
Between-run precision
A measure of between-run precision was estimated by aver-
aging the coefficients of variation from the analysis of six replicate
samples run over 3 days (n = 18). The average between-run preci-
sion was 11.2%, 4.4%, and 3.0% for samples at concentrations of
1, 10, and 100 ng/mL, respectively.
Accuracy
Accuracy was determined as a percentage of calculated concen-
tration over the actual concentration. An assay of six replicate
samples at 1, 10, and 100 ng/mL gave calculated accuracy values
of 126.5%, 98.6 %, and 100.1%, respectively.
Selectivity
An analysis of blank plasma samples showed there were no
interfering peaks at the elution time of either oxycodone or the
internal standard.
Stability
Smith (11) reported that oxycodone was stable in plasma sam-
ples stored at –20°C for up to 6 months.
Extracted oxycodone samples were stable for at least 24 h at
room temperature. There was no significant difference (α = 0.05)
for samples reanalyzed after storage in the autosampler carousel
for 24 h at concentrations of 1, 10, and 100 ng/mL (n = 6 at each
concentration).
Samples were stable following three freeze/thaw cycles. There
was no significant difference (α = 0.05) for samples reanalyzed
after three freeze/thaw storage cycles at concentrations of 1, 10,
and 100 ng/mL (n = 6 at each concentration).
Application of the method
Clinical studies were carried out in which an intravenous infu-
sion dose of oxycodone was given for 60 min (dose concentrations
ranged from 5 to 15 mg). Samples were taken over a period of 3 h
after the dose. A blank sample was taken prior to dosing to deter-
mine whether there were any interfering ions. None of the blank
samples for the subjects enrolled in the study contained inter-
fering ions at the two transitions studied (i.e., m/z 316.1 → 298.1
and m/z 328.1 → 310.1). It was possible to quantitate oxycodone
levels over the period for which respiratory data were gathered for
all subjects enrolled in the study. A typical oxycodone concentra-
tion-time profile following a single intravenous infusion of 5 mg
is shown in Figure 5.
Conclusion
The LC–electrospray ionization–MS–MS method described has
been used to process more than 3000 plasma samples. All calibra-
tion curves had a correlation coefficient greater than 0.9989 over
the plasma concentration range of 1 to 100 ng/mL. Although
some previously reported methods have achieved similar limits of
quantitation, the method reported in this study requires signifi-
cantly less sample preparation, and the very short run time allows
for very high sample throughput.
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